Post-Plunge: Is Sarepta a Bad News Buy?

From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Check-Up covers the health care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

Shares of Sarepta Therapeutics  (NASDAQ: SRPT  ) plunged more than 60% earlier this week on news that Food and Drug Administration thinks it's too early to file a new drug application for its Duchenne muscular dystrophy drug eteplirsen. The market sell-off was also spurred in part by a competing drug in this space from GlaxoSmithKline (NYSE: GSK  ) and Prosensa (UNKNOWN: RNA.DL  ) that failed its phase 3 trials. In this segment from Tuesday's episode, health care analyst David Williamson discusses whether investors who believe in this drug should consider this sell-off a buying opportunity, and why those looking to buy on the dip may need a healthy dose of patience.

One growth stock to watch today
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!

Editor's Note: This video was filmed on Nov. 12, 2013.

Follow David on Twitter: @MotleyDavid.

Read/Post Comments (3) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 14, 2013, at 5:22 PM, fbert wrote:

    prosensa fails and serpta is punished even though the side affects were non existent with the serepta drug. Why can't the parents decide whether or not their children get a chance to live rather then the FDA??

  • Report this Comment On November 15, 2013, at 3:42 PM, SierraSQ wrote:

    There is a rumor floating around that GSK is making a bid to buy Sarepta at $18 over the weekend.

  • Report this Comment On November 15, 2013, at 5:42 PM, bamobrien wrote:

    fbert: side effects had nothing to do with why sarepta was denied AA.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2726962, ~/Articles/ArticleHandler.aspx, 9/30/2016 8:11:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
SRPT $61.41 Up +0.43 +0.71%
Sarepta Therapeuti… CAPS Rating: **
GSK $43.13 Up +0.23 +0.54%
GlaxoSmithKline CAPS Rating: ***
RNA.DL $0.00 Down +0.00 +0.00%
Prosensa Holding CAPS Rating: **